

### 1. Details of shareholder

- Full legal name of shareholder: \_\_\_\_\_
- Country of tax residence establishment: \_\_\_\_\_
- Address, postal code, and city: \_\_\_\_\_
- Tax identification number: \_\_\_\_\_

### 2. Specification of Dividends

- Number of CureVac shares held on [January 5, 2026]: \_\_\_\_\_
- Beneficiary of CureVac shares: \_\_\_\_\_
- Country code of residence: \_\_\_\_\_
- Date of receipt of the total post-offer reorganization (BioNTech ADSs and cash in lieu) (dd-mm-yyyy): \_\_\_\_\_
- Total post-offer reorganization consideration received (no. of BioNTech ADSs and cash in lieu received): \_\_\_\_\_

### 3. Further details

- Name of contact person: \_\_\_\_\_
- Position: \_\_\_\_\_
- Address: \_\_\_\_\_
- Telephone: \_\_\_\_\_
- Date: \_\_\_\_\_
- Account holder: \_\_\_\_\_
- Bank: \_\_\_\_\_
- SWIFT Code: \_\_\_\_\_
- Bank Account Currency: \_\_\_\_\_
- IBAN/ Bank Account Number: \_\_\_\_\_

4. By signing the below, the shareholder hereby declares:

- It is under Dutch law the beneficial owner of the consideration received by the Minority Shareholders pursuant to the terms of the Offer;
- It is not a resident nor deemed to be resident in the Netherlands for Dutch income tax purposes or Dutch corporation tax purposes;
- It is not a shareholder who derives profits from an enterprise which enterprise is carried on, in whole or in part, through a permanent establishment or a permanent representative in the Netherlands; and
- It is hereby attaching proof of tax residency.

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

Date: \_\_\_\_\_